Treating the meytabolic syndrome: Acetyl-CoA carboxylase inhibition

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 2, 2005, Pages 267-281

  Harwood Jr , H James ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Acetyl CoA carboxylase (ACC); Enzyme inhibition; Fatty acid oxidation; Fatty acid synthesis; Metabolic syndrome

Indexed keywords

1 (5 TETRADECYLOXY 2 FURANYL)ETHANONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3,3,14,14 TETRAMETHYLHEXADECANEDIOIC ACID; 8 HYDROXY 2,2,14,14 TETRAMETHYLPENTADECANEDIOTIC ACID; ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE ENHIBITOR; ACETYLSALICYLIC ACID; BENZOIC ACID DERIVATIVE; BIGUANIDE; CHOLESTEROL; CP 640186; CPP 640186; CYCLOHEXANE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENZYME INHIBITOR; ESP 55016; FATTY ACID; FIBRIC ACID DERIVATIVE; FUNGICIDE; HALOXYFOP; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISOENZYME; LIGASE INHIBITOR; LIPID; MALONYL COENZYME A; NICOTINIC ACID; SETHOXYDIM; SORAPHEN A; SULFONAMIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CELL CULTURE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE MODEL; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG SELECTIVITY; DRUG STRUCTURE; DYSLIPIDEMIA; ENZYME INHIBITION; EXERCISE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; HAMSTER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INHIBITION KINETICS; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; MEDICAL LITERATURE; METABOLIC SYNDROME X; MONKEY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATENT; PATIENT EDUCATION; PRACTICE GUIDELINE; RAT; REVIEW; RISK ASSESSMENT; RISK FACTOR; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; WEIGHT REDUCTION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM;

ACETYL-COA CARBOXYLASE; ANIMALS; ENZYME INHIBITORS; FATTY ACIDS; HUMANS; METABOLIC SYNDROME X;

EID: 18144396604     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.2.267     Document Type: Review

References (100)

1. REAVEN GM: Role of insulin resistance in human disease. Diabetes (1988) 37:1595-1607.
2. HOWARD BV: Epidemiology of the plurimetabolic syndrome. In: Atherosclerosis X. Woodford FP, Davignon J, Sniderman A, Eds. Elsevier Science B.V. New York, NY. (1995):516-519.
3. CREPALDI G: Pleurimetabolic syndrome or syndrome X: an overview. In: Atherosclerosis X. Woodford FP, Davignon J, Sniderman A (Eds.) Elsevier Science B.V. New York, NY. (1995):511-515.
4. FORD ES, GILES WH, DIETZ WH: Prevalence of the metabolic syndrome among US adults, findings from the Third National Health and Nutrition Examination Survey. J. Am. Med. Assn. (2002) 287:356-359.
5. NATIONAL CHOLESTEROL EDUCATION PROGRAM EXPERT PANEL: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J. Am. Med. Assn. (2001) 285:2486-2497.
6. ALBERTI KGMM, ZIMMET PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: provisional report of a WHO consultation. Diabet. Med. (1998) 15:539-553.
7. MOLLER DE: New drug targets for type-2 diabetes and the metabolic syndrome. Nature (2001) 414:821-827.
8. GRUNDY SM, BREWER HB, CLEEMAN JI, SMITH SC, LENFANT C: Definition of metabolic syndrome. Circulation (2004) 109:433-438.
9. GRUNDY SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. (1999) 83:25F-29F.
10. SOLYMOSS BC, BOURASA MG, CAMPEAU L et al.: Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am. J. Cardiol. (2004) 93:159-164.
11. HAFFNER SM, VALDEZ RA, HAZUDA HP, MITCHELL BD, MORALES PA, STREN MP: Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes (1992) 41:715-722.
12. ISOMAA B, ALMGREN P, TUOMI T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 24:683-689.
13. TREVISAN M, LIU J, BAHSAS FB, MENOTTI A: Syndrome X and mortality: a population-based study. Risk factor and life expectancy research group. Am. J. Epidemiol. (1998) 148:958-966.
14. VGONTZAS AN, BIXLER EO, CHROUSOS GP: Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J. Int. Med. (2003) 254:32-44.
15. SEPPALA A, VEHKAVAARA S, HAKKINEN AM et al.: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endo. Metabol. (2002) 87:3023-3028.
16. EINHORN D, REAVEN GM, COBIN RH, et al.: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. (2003) 9:237-252.
17. SATTAR N, GAW A, SCHERBAKOVA O: The metabolic syndrome with and without C-reactive proteinas a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 108:414-419.
18. MUDALIAR S, HENRY R, HELWICK CA: Diabetes and cardiovascular disease. The Endrocrinol. (2003)13:S1-S2.
19. AMERICAN DIABETES ASSOCIATION: Management of dyslipidemia in adults with diabetes. Diabetes care (2004) 27:S68-S71.
20. GRUNDY SM, HANSEN B, SMITH SC, CLEEMAN JI, KAHN RA: Clinical management of metabolic syndrome. Circulation (2004) 109:551-556.
21. AMERICAN DIABETES ASSOCIATION: Treatment of hypertension in adults with diabetes. Diabetes care (2004) 27:S65-S67.
22. AMERICAN DIABETES ASSOCIATION: Aspirin therapy in diabetes. Diabetes care (2004) 27:S72-S73.
23. AMERICAN DIABETES ASSOCIATION: The prevention or delay of type-2 diabetes. Diabetes care (2004) 27:S47-S54.
24. BJORNTORP P: Fatty acids, hyperinsulinemia, and insulin resistance: which comes first? Curr. Opin. Lipidology (1994) 5:166-174.
25. DEPRES JP, MARETTE A: Relation of components of insulin resistance syndrome to coronary disease risk. Curr. Opin. Lipidology (1994) 5:274-289.
26. MCGARRY JD: What if Minkowski had been ageusic? An alternative angle on diabetes. Science (1992) 258:766-770.
27. BERGMAN RN, CITTERS GW, MITTELMAN SD, DEA MK, HAMILTON-WESSLER M, KIM SP: Central role of the adipocyte in the metabolic syndrome. J. Invest. Med. (2001) 49:119-126.
28. MCGARRY JD, DOBBINS RL: Fatty acids, lipotoxicity and insulin secretion. Diabetologia (1999) 42:128-138.
29. RODEN M: How free fatty acids inhibit glucose utilization in human skeletal muscle. News Physiol. Sci. (2004) 19:92-96.
30. RUDERMAN N, PRENTKI M: AMP kinase and malonyl-CoA: targets for the therapy of the metabolic syndrome. Nat. Rev. Drug Discov. (2004) 3:340-351.
31. SHI Y, BURN P: Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat. Rev. Drug Discov. (2004) 3:695-710.
32. AN J, MUOIO DM, SHIOTA M et al.: Hepatic expression of malonyl-CoA carboxylase reverses muscle, liver and whole animal insulin resistance. Nat. Med. (2004) 10:268-274.
33. KIM KH: Regulation of mammalian acetyl-CoA carboxylase. Ann. Rev. Nutr. (1997) 17:77-99.
34. 2+-dependent phosphatase. J. Biol. Chem. (1985) 260:6318-6323.
35. HASHIMOTO T, NUMA S: Kinetic studies on the reaction mechanism and the citrate activation of liver acetyl-CoA carboxylase. Eur. J. Biochem. (1971) 18:319-331.
36. BEATY NM, LANE MD: Acetyl-CoA carboxylase, rapid purification of the chick liver enzyme and steady state analysis of the carboxylase-catalyzed reaction. J. Biol. Chem. (1982) 257:924-929.
37. ZHANG H, YANG Z, SHEN Y, TONG L: Crystal structure of the carboxyltransferase domain of acetyl-CoA carboxylase. Science (2003) 299:2064-2067.
38. MCGARRY JD, FOSTER DW: Regulation of hepatic fatty acid oxidation and ketone body production. Ann. Rev. Biochem. (1980) 49:395-420.
39. MUNDAY MR, HEMINGWAY CJ: The regulation of acetyl-CoA carboxylase - potential target for the action of hypolipidemic agents. Adv. Enzyme Reg. (1999) 39:205-234.
40. SHEN Y, VOLRATH SL, WEATHERLY SC, ELICH TD, TONG L: A mechanism for the potent inhibition of eukaryotic acetyl-CoA carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol. Cell (2004) 16:881-889.
41. ZHANG H, TWEEL B, LI J, TONG L: Crystal structure of the carboxyltransferase domain of acetyl-CoA carboxylase in complex with CP-640186. Structure (2004) 12:1683-1691.
42. ZHANG H, TWEEL B, TONG L: Molecular basis for the inhibition of the carboxyltransferase domain of acetyl-CoA carboxylase by haloxyfop and diclofop. Proc. Natl. Acad. Sci USA (2004) 101:5910-5915.
43. ALLRED JB, REILLY KE: Short-term regulation of acetyl-CoA carboxylase in tissues of higher animals. Prog. Lipid Res. (1996) 35:371-385.
44. ABU-ELHEIGA L, OH W, KORDARI P, WAKIL SJ: Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high fat/high carbohydrate diets. Proc. Natl. Acad. Sci. (USA) (2003) 100:10207-10212.
45. TRUMBEL GE, SMITH MA, WINDER WW: Purification and characterization of rat skeletal muscle acetyl-CoA carboxylase. Eur. J. Biochem (1995) 231:192-198.
46. OGIWARA T, TANABE T, NIKAWA JI, NUMA S: Inhibition of rat liver acetyl-CoA carboxylase by palmitoyl-CoA, formation of equimolar enzyme-inhibitor complex. Eur. J. Biochem. (1978) 89:33-41.
47. OH SY, LEE MY, KIN JM et al.: Alternative usages of multiple promoters of the acetyl-CoA carboxylase β gene are related to differential transcriptional regulation in human and rodent tissues. J. Biol. Chem. (2004) Paper In Press. published online as M409037200.
48. BRUN T, ROCHE E, Assimacopoulos-Jeannet F, Corkey BE, Kim KH, Premki M: Evidence for an anaplerotic/malonyl-CoA pathway in pancreatic β-cell signaling. Diabetes (1996) 45:190-198.
49. MCGARRY JD, WOELTJE KF, KUWAJIMA M, FOSTER DW: Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab. Rev. (1989) 5:271-284.
50. MCGARRY JD, BROWN NF: The mitochondrial carnitine palmitoyltransferase system, from concept to molecular analysis. Eur. J. Biochem. (1997) 244:1-14.
51. BUCKLEY MG, RATH EA: Regulation of fatty acid synthesis and malonyl-CoA content in mouse brown adipose tissue in response to cold exposure, starvation or re-feeding. Biochem. J. (1987) 243:437-442.
52. SAHA A, KUROWSKI TG, RUDERMAN NB: A malonyl-CoA fuel-sensing mechanism in muscle: effects of insulin, glucose, and denervation. Am. J. Physiol. (Endocrinol. Metab.) (1995) 269:E283-E289.
53. RASMUSSEN BB, HOLMBACK UC, VOLPI E, MORIO-LIONDORE B, PADDON-JONES D, WOLFE RR: Malonyl-CoA and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J. Clin. Invest. (2002) 110:1687-1693.
54. HU Z, CHA SH, CHOHNAN S, LANE MD: Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc. Natl. Acad. Sci. USA (2003) 100:12624-12629.
55. THUPARI JN, LANDREE LE, RONNETT GV, KUHAJDA FP: C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc. Natl. Acad. Sci. USA (2002) 99:9498-9502.
56. CHEN S, OGAWA A, OHNEDA M, UNGER RH, FOSTER DW, MCGARRY JD: More direct evidence for a malonyl-CoA - carnitine palmitoyltransferase-1 interaction as a key event in pancreatic β-cell signaling. Diabetes (1994) 43:878-883.
57. BIANCHI A, EVANS JL, IVERSON AJ, NORDLUND AC, WATTS TD, WITTERS LA: Identification of an isozymic form of acetyl-CoA carboxylase. J. Biol. Chem. (1990) 265:1502-1509.
58. IVERSON AJ, BIANCHI A, NORDLUND AC, WITTERS LA: Immunological analysis of acetyl-CoA carboxylase mass, tissue distribution, and subunit composition. Biochem. J. (1990) 269:365-371.
59. WIDMER J, FASSIHI KS, SCHLICHTER SC et al.: Identification of a second human acetyl-CoA carboxylase gene. Biochem. J. (1996) 316:915-922.
60. HA J, LEE JK, JIM KS, WITTERS LA, KIM KH: Cloning of human acetyl-CoA carboxylase-R and its unique features. Proc. Natl. Acad. Sci. USA (1996) 93:11466-11470.
61. ABU-ELHEIGA L, ALMARZA-ORTEGA DB, BALDINI A, WAKIL SJ: Human acetyl-CoA carboxylase 2, molecular cloning, characterization, chromosomal mapping, and evidence of two isoforms. J. Biol. Chem. (1997) 272:10669-10677.
62. ABU-ELHEIGA L, MATZUK MM, ABO-HASHEMA KAH, WAKIL SJ: Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science (2001) 291:2613-2616.
63. ABU-ELHEIGA L, BRINDLEY WR, ZHONG L, CHIRALA SS, WOLDEGIORGIS G, WAKIL SJ: The subcellular localization of acetyl-CoA carboxylase 2. Proc. Natl. Acad. Sci. USA (2000) 97:1444-1449.
64. MCCUNE SA, HARRIS RA: Mechanism responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of hepatic lipogenesis. J. Biol. Chem. (1979) 254:10095-10101.
65. ARBEENY CM, MEYERS DS, BERGQUIST KE, GREGG RE: Inhibition of fatty acid synthesis decreases VLDL secretion in the hamster. J. Lipid Res. (1992) 33:843-851.
66. KEMPEN HJ, IMBACH AP, GILLER T, NEUMANN WJ, HENNES U, NAKADA N: Secretion of apoA1 and apoB by HepG2 cells: regulation by substrates and metabolic inhibitors. J. Lipid Res. (1996) 36:1796-1806.
67. PARKER RA, KARIYA T, GRISAR JM, PETROW V: 5-(tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. J. Med. Chem. (1977) 20:781-791.
68. FUKUDA N, ONTKO JA: Interactions between fatty acid synthesis, oxidation, and esterification in the production of triglyceride-rich lipoproteins by the liver. J. Lipid Res. (1984) 25:831-842.
69. TRISCARI J, SULLIVAN AC: Anti-obesity activity of a novel lipid synthesis inhibitor. Int. J. Obesity (1984) 8 (Suppl.1):227-239.
70. HARWOOD HJ Jr, PETRAS SF, SHELLY LD et al.: Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J. Biol. Chem. (2003) 278:37099-37111.
71. YANG N, KAYS JS, SKILLMAN TR, BURRIS L, SENG TW, HAMMOND C: C75 (4-methylene-2-octyl-5-oxo-tetrahydrofuran-3-carboxylic acid) activates carnitine palmitoyltransferase-1 in isolated mitochondria and intact cells without displacement of bound malonyl-CoA. J. Pharm. Expl. Ther. (2005) 312:127-133.
72. HARWOOD HJ Jr, PETRAS SF, SHELLY LD, SOLIMAN VF, PERRY DA: Acetyl-CoA carboxylase inhibition by CP-640186 reduces liver, muscle and adipose tissue fat content, reduces body weight and percentage body fat, and improves insulin sensitivity in rats with diet-induced metabolic syndrome. (2005) In preparation.
73. PERRY DA, HARWOOD HJ Jr, MAKOWSKI MR et al.: Nipecotic acid derivatives as potent, nonselective acetyl-CoA carboxylase inhibitors: a novel approach for obesity. Proceedings of the 228th ACS National Meeting, Philadelphia USA (2004) MEDI 197.
74. GERTH K, PRADELLA S, PERLOVA O, BEYER S, MULLER R: Myxobacteria: proficient producers of novel natural products with various biological activities - past and future biotechnological aspects with the focus on the genus Sorangium. J. Biotechnol. (2003) 106:233-253.
75. VAHLENSIECK HF, PRIDZUN L, REICHENBACH H, HINNEN A: Identification of the yeast ACC1 gene product (acetyl-CoA carboxylase) as the target of the polyketide fungicide soraphen A. Curr. Genet. (1994) 25:95-100.
76. WEATHERLY SC, VOLRATH SL, ELICH TD: Expression and characterization of recombinant fungal acetyl-CoA carboxylase and isolation of a soraphen-binding domain. Biochem. J. (2004) 380:105-110.
77. SASAKI Y, KONISHI T, NAGANO Y: The compartmentalization of acetyl-CoA carboxylase in plants. Plant Physiol. (1995) 108:445-449.
78. GRONWALD JW: Herbicides inhibiting acetyl-CoA carboxylase. Biochem. Soc. Trans. (1994) 22:616-621.
79. HARWOOD JL: Recent advances in the biosynthesis of plane fatty acids. Biochim. Biophys. Res. Commun. (1996) 1301:7-56.
80. ZAGNITKO O, JELENSKA J, TEVZADZE G, HASELKORN R, GORNICKI P: An isoleucine/leucine residue in the carboxyltransferase domain of acetryl-CoA carboxylase is critical for interaction with aryloxyphenoxypropionate and cyclohexanedione inhibitors. Proc. Natl. Acad. Sci USA (2001) 98:6617-6622.
81. SENG TW, SKILLMAN TR, YANG N, HAMMOND C: Cyclohexanedione herbicides are inhibitors of rat heart acetyl-CoA carboxylase. Bioorg. Med. Chem. Letts. (2003) 13:3237-3242.
82. KEMAL C, CASIDA JE: Coenzyme A esters of 2-aryloxyphenoxypropionate herbicides and 2-arylpropionate anti-inflammatory drugs are potent and stereoselective inhibitors of rat liver acetyl-CoA carboxylase. Life Sci. (1992) 50:533-540.
83. TANABE T, NAKANISHI S, HASHIMOTO T, OGIWARA H, NIKAWA JI, NUMA S: Acetyl-CoA carboxylase from rat liver. Meth. Enzymol. (1981) 71:5-16.
84. NIKAWA JI, TANABE T, OGIWARA H, SHIBA T, NUMA S: Inhibitory effects of long-chain acyl-CoA analogs on rat liver acetyl-CoA carboxylase. FEBS Lett. (1979) 102:223-225.
85. CRAMER CT, GOETZ B, HOPSON KLM et al.: Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J. Lipid Res. (2004) 45:1289-1301.
86. ROSE-KAHN G, BAR-TANA J: Inhibition of rat liver acetyl-CoA carboxylase by β, β'-tetramethyl-substituted hexadecanedioic acid (MEDICA 16). Biochim. Biophys. Acta (1990) 1042:259-264.
87. OHMORI K, YAMADA H, YASUDA A, YAMAMOTO A, MATSUURA N, KINIWA M: Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S2E. Eur. J. Pharmacol. (2003) 471:69-76.
88. WHITTINGTON M, ENSER M, PRATT J, RIDDELL D, ASHTON MJ: Effect of sodium 2-n-pentadecyl-benzimidazole-5-carboxylate (M&B-35347B), an inhibitor of acetyl-CoA carboxylase, on lipogenesis and fat deposition in obese hyperglycaemic (ob/ob) and lean mice. Int. J. Obesity (1987) 11:619-629.
89. ATKINSON LL, KELLY SE, RUSSELL JC, BAR-TANA J, LOPASCHUK GD: MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR:LA-cp rats. Diabetes (2002) 51:1548-1555.
90. RUSSELL JC, SHILLABEER G, BAR-TANA J et al.: Development of insulin resistance in the JCR:LA-cp rat. Diabetes (1998) 47:770-778.
91. GROOT PHE, PEARCE NJ, GRIBBLE AD: ATP-citrate lyase: potential target for hypolipidemic intervention. Curr. Med. Chem.-Immun. Endoc. & Metab. Agents (2003) 3:211-217.
92. LEVERT KL, WALDROP GL: A bisubstrate analog inhibitor of the carboxyltransferase component of acetyl-CoA carboxylase. Biochem. Biophys. Res. Commun. (2002) 291:1213-1217.
93. LEVERT KL, WALDROP GL, STEPHENS JM: A biotin analog inhibits acetyl-CoA carboxylase activity and adipogenesis. J. Biol. Chem. (2002) 277:16347-16350.
94. BALKAU R, CHARLES MA: Comment on the provisional report from the WHO consultation. Diabet. Med. (1999) 16:442-443.
95. OH W, ABU-ELHEIGA L, KORDARI P et al.: Glucose and fat metabolism in adipose tissue of ACC2 knockout mice. Proc. Natl. Acad. Sci. (USA) (2005) 102:1384-1389.
96. TREADWAY JL, MCPHERSON RK, PETRAS SF et al.: Effect of the Acetyl-CoA carboxylase inhibitor CP-640186 on glycemic control in diabetic ob/ob mice. Diabetes (2004) 53 (Suppl. 2):A162.
97. ATKINSON LL, KOZAK R, KELLY SE, ONAY-BESIKCI A, RUSSELL JC, LOPASCHUK GD: Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am. J. Physiol. Endocrinol. Metab. (2003) 284:E923-E930.
98. CHIU HC, KOVACS A, FORD DA et al.: A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. (2001) 107:813-822.
99. SAMBANDAM N, LOPASCHUK GD: AMP-activated protein kinase control of fatty acid and glucose metabolism in the ischemic heart. Prog. Lipid Res. (2003) 42:238-256.
100. LOPASCHUK GD: Targets for modulation of fatty acid oxidation in the heart. Curr. Opin. Invest. Drugs. (2004) 5:290-294.